Aztreonam is a monobactam antibacterial with enhanced beta-lactamase stability, targeted to aerobic Gram-negative bacteria, including Pseudomonas spp. Cayston is administered by inhalation using a nebulizer.

**Pre-Authorization Criteria:** cystic fibrosis (CF) patients over 7 years old with known infection with Pseudomonas aeruginosa

**Dosing:** 75 mg three times a day for 28 days via nebulizer, after pre-treatment with a bronchodilator

**How Supplied:** 75 mg in single-use vial to be reconstituted with 1 mL diluent

**Contraindications/Warnings:** known allergy to aztreonam

**Major Adverse Reactions:** cough; acute bronchospasm; rebound decrease in FEV1 after course of therapy

**Major Drug Interactions:** none described

**REFERENCES**


**Revision History:**

Date Approved by P&T Committee: 04.22.14
Date Reviewed/Updated: 02.17.15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16
Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>